Retinal screening should be infrastructure — not a service.
RetGuard is a medical AI company based in Delaware, United States. We design screening systems that clinics own and operate independently — hardware, software, and clinical intelligence in a single package with no external dependencies.
Our thesis: the economics of per-test cloud billing are fundamentally misaligned with population-level screening. We built the alternative.
RetGuard Inc.
Delaware, United States
We build the intelligence layer. We partner for the optics.
RetGuard owns the full AI stack — model architecture, training pipelines, clinical validation, and the edge inference platform. For imaging hardware, we partner with established ophthalmic manufacturers who have decades of experience building clinical-grade cameras.
What we own
- AI model architecture and training
- Edge inference platform (RetGuard Box)
- Clinical validation and regulatory
- Screening software and report generation
What we partner for
- Fundus camera manufacturing
- OCT device manufacturing
- Optical component sourcing
- Regional distribution and service
Where we're going
We're expanding our screening pipeline beyond the retina. The same edge-first architecture that powers RetGuard today can be applied to other imaging modalities and diagnostic workflows — anywhere a clinic needs clinical-grade AI without clinical-grade infrastructure.
Our next milestone: applying the same architecture to prostate cancer screening — bringing edge-first diagnostic AI to one of the most common cancers worldwide.